**INTRODUCTION**

The role of P-glycoprotein (P-gp), the encoded product of the MDR1 gene, has been extensively studied as a mediator of multidrug resistance phenotype associated with certain types of cancers. Constitutive expression of this transporter in normal tissues has been shown to play an important role in drug disposition and response. More recently, genetic heterogeneity in terms of single nucleotide polymorphisms (SNPs) in this transporter has received significant attention as potential determinant of susceptibility to inflammatory bowel disease (IBD), and variability in drug efficacy in this condition.

The goal of this review is to summarize the available knowledge regarding the role of P-gp in the human gastrointestinal tract and on drug disposition process, and to focus specifically on the putative effects of the MDR1 gene polymorphisms in IBD by means of a meta-analysis of the available studies.

**P-GP FUNCTION**

P-gp is a member of the adenosine triphosphate (ATP)-binding cassette family that is encoded by the human ABCB1 gene (ATP-binding cassette, subfamily B), also called MDR1[1]. Human P-gp is a phosphorylated and glycosilated transmembrane protein consisting of 1280 amino acids and 2 homologous and symmetric sequences, each containing 6 transmembrane domains and an ATP-binding motif. P-gp functions as a transmembrane efflux pump, thereby moving drugs from the intracellular to the extra cellular domain; it may also interact with drug molecules trapped within the cell membrane lipid bilayer. ATP hydrolysis provides the energy for active drug transport against steep concentration gradient.
P-gp IN THE GASTROINTESTINAL TRACT

In the human gastrointestinal tract (GI), P-gp is found at high concentrations on apical surfaces of superficial columnar epithelial cells of the colon and distal small bowel. High levels are also found in small biliary ductules and small pancreatic ductules[5]. In the GI tract there is a regional variation in P-gp expression with a maximal expression in the epithelial cells of the ileum and a gradual decline proximally to the jejunum, duodenum, and stomach; variations across the colon are less well defined[10]. The putative role of the P-gp in the GI tract is to decrease the absorption of endogenous and exogenous hydrophobic amphipathic toxins[11,12]. A great insight into the physiological role of P-gp protein in the GI tract has derived from the phenotype of the mdr1a gene knockout mice. This model was prompted by the finding that the MDR1 gene is present in a region of the human genome (7q21.1) that may harbour a disease gene involved in susceptibility to IBD[13]. Interestingly, the mdr1a knockout mice also develop a spontaneous colitis when maintained under specific pathogen-free conditions[14]. The colitis is prevented and reversed by the administration of antibiotics, suggesting that the intestinal flora is necessary to initiate and perpetuate the inflammation. This model implies that loss of the xenobiotic efflux mechanism may lead to decreased bioavailability, distribution, and excretion of drugs. Evidence supporting such a role was obtained from experiments with P-gp knockout mice in genetically susceptible animals. A mouse strain naturally deficient in mdr1a demonstrated a marked sensitivity to the neurotoxic effects of ivermectin, an antiparasiticide[15]. Experiments with mdr1a knockout mice have revealed the P-gp limits the central nervous system entry of drugs like cyclosporine, digoxin, vinblastine[16] and the oral absorption of drug like paclitaxel[17]. Of broad clinical relevance is the interaction between P-gp and the xenobiotic efflux mechanism with other important transporters in the GI tract (like a “vacuum cleaner”)[18]. P-gp was first isolated from colchicine-resistant Chinese hamster ovary cells[19]. Subsequently the gene coding for P-gp (MDR1) was identified owing to its over expression in tumour cells associated with an acquired cross-resistance to multiple cytotoxic anticancer agents[20]. In humans, two MDR genes, MDR1 and MDR3 (also called MDR2), have been described, whereas in rodents three genes mdr1a, mdr1b, mdr2, have been identified. Subsequently, P-gp was also recognized to be expressed in many normal tissues, such as the canalicul surface of hepatocytes, the apical surface of proximal tubular cells in kidneys, and the brush borders of the enterocytes[21]. In addition, P-gp is also found in the epithelium of the brain choroids plexus (where constitutes the blood-cerebrospinal fluid barrier) as well as on the luminal surface of blood capillaries of the brain (blood-brain barrier)[22]. P-gp is also expressed in other tissues known to have blood-tissues barriers, such as placenta, ovaries, and testes[23]. Moreover, P-gp has been detected in haematopoietic stem cells, peripheral blood mononuclear cells, mature macrophage, natural killer cells, antigen-presenting dendritic cells, and T and B-lymphocytes[24].

The function and especially the anatomic localization of P-gp suggest that this transporter acts as a protective barrier to keep toxins out of the body by secreting them into bile, urine, and intestinal lumen, and thereby preventing their accumulation in critical organs[25].

Helicobacter bilis infection accelerated while Helicobacter helpticus infection delayed the development of spontaneous colitis[26], thus suggesting that specific luminal bacteria may critically influence the development of colitis in genetically susceptible animals.

P-gp SUBSTRATES

The structure-activity relationship for P-gp substrates has yet to be clearly defined. Table 1 summarizes a comprehensive list of compounds that act as substrates, inhibitors or inducers of P-gp (modified from Marzolini et al)[27]. The range of substrates is broad and it also evident that many drugs are also substrates of the cytochrome P450 (CYP) 3A4. The overlap between CYP3A4 and P-gp is also emphasized by the genomic proximity of both genes (7q22.1 and 7q21.1 for CYP3A4 and MDR1, respectively)[28]. The co-localization of the P-gp and CYP3A4 in the small intestine and liver suggests that this transporter also plays a significant role in the oral bioavailability, distribution, and excretion of drugs. Evidence supporting such a role was obtained from animal models. A mouse strain naturally deficient in mdr1a demonstrated a marked sensitivity to the neurotoxic effects of ivermectin, an antiparasiticide[29]. Experiments with mdr1a knockout mice have revealed the P-gp limits the central nervous system entry of drugs like cyclosporine, digoxin, vinblastine[30] and the oral absorption of drug like paclitaxel[31]. Of broad clinical relevance is the interaction between P-gp and the xenobiotic efflux mechanism with other important transporters in the GI tract (like a “vacuum cleaner”). P-gp was first isolated from colchicine-resistant Chinese hamster ovary cells. Subsequently the gene coding for P-gp (MDR1) was identified owing to its over expression in tumour cells associated with an acquired cross-resistance to multiple cytotoxic anticancer agents. In humans, two MDR genes, MDR1 and MDR3 (also called MDR2), have been described, whereas in rodents three genes mdr1a, mdr1b, mdr2, have been identified. Subsequently, P-gp was also recognized to be expressed in many normal tissues, such as the canalicul surface of hepatocytes, the apical surface of proximal tubular cells in kidneys, and the brush borders of the enterocytes. In addition, P-gp is also found in the epithelium of the brain choroids plexus (where constitutes the blood-cerebrospinal fluid barrier) as well as on the luminal surface of blood capillaries of the brain (blood-brain barrier). P-gp is also expressed in other tissues known to have blood-tissues barriers, such as placenta, ovaries, and testes. Moreover, P-gp has been detected in haematopoietic stem cells, peripheral blood mononuclear cells, mature macrophage, natural killer cells, antigen-presenting dendritic cells, and T and B-lymphocytes.

The function and especially the anatomic localization of P-gp suggest that this transporter acts as a protective barrier to keep toxins out of the body by secreting them into bile, urine, and intestinal lumen, and thereby preventing their accumulation in critical organs.

| DRUG       | $ | I- | I+ |
|------------|--|--|--|
| Anticancer | √ |   |   |
| Actinomycin D | √ | Amprenavir | √ |
| Daunorubicin | √ | Indinavir | √ |
| Mitomycin C | √ | Nelfinavir | √ |
| Mitoxantrone | √ | Antibiotics | √ |
| Vinblastine | √ | Claritromycin | √ |
| Vinricetine | √ | Erythromycin | √ |
| Antihypertensives | √ | Levotiroxcin | √ |
| Dilatazem | √ | Rifampin | √ |
| Losartan | √ | Tetracycline | √ |
| Nicardipine | √ | Antimycotics | √ |
| Talinolol | ± | Itraconazole | √ |
| Antiarrhythmics | √ | Ketocanazone | √ |
| Amiodarone | √ | Immunosup. | √ |
| Digital | √ | Cyclosporine | √ |
| Quinidine | √ | Tacrolimus | √ |
| Verapamile | √ | Methotrexate | √ |
| Glucocorticoids | √ | Antidepressants | √ |
| Aldosterone | √ | Amitriptiliny | √ |
| Cortisol | √ | Fluoxetine | √ |
| Dexemethasone | √ | Neuroleptics | √ |
| Methylprednisolone | √ | Chlorpromazine | √ |
| Others | √ | Phenotizine | √ |
| Colchicine | √ | Phenobarbital | √ |
| Dipyridamole | √ | Opioids | √ |
| Loperamide | √ | Methadone | √ |
| Progestosterone | √ | Morphine | √ |
| Spiromolactone | √ | Antacids | √ |
| Domperidone | √ | Ranitidine | √ |
| Ondansetron | √ | Cimetidine | √ |
between digoxin and other cardiac drugs such as verapamil, quinidine, and amiodarone. Of interest, several drugs central to IBD therapy are also MDR1 substrates like glucocorticoids, cyclosporine and methotrexate.

**POLYMORPHISM IN THE HUMAN MDR1 GENE**

MDR1 is located in the human chromosome 7 band p21-21.1 on a 600 kb NruI fragment, and the MDR1 coding region is contained on a 120 kb XhoI fragment. The gene extends over more than 100 kb containing 28 introns, 26 of them interrupting the protein-coding sequence. MDR1 mRNA has a size of 4.7 kDa, thus its coding region accounts for less than 5% of the total. The first report of MDR1 polymorphism was presented in 1989. To date, genetic variations of the human MDR1 gene have been extensively studied (reviewed in ref.28, 29) with 50 SNPs and 3 insertion/deletion polymorphisms reported. Moreover, several preclinical and clinical studies have provided evidence for naturally occurring polymorphisms of MDR1 gene and their effects on drug absorption, distribution, and elimination. Hoffmeyer et al performed the first systematic screening for MDR1 polymorphisms in 2000; in that study a synonymous SNP in exon 26 (C3435T) was the first variation to be associated with altered protein expression, although the SNP does not change the encoded amino acid (Ile). In addition, P-gp expression in the duodenum of individuals with the homozygous T allele (variant) was decreased when compared with individuals with the C allele (wild type). Other studies have shown that SNPs at exon 21 (G2677T/A) and at exon 1b (T129C) may also be associated with altered transport function or expressions. However, a disequilibrium exists between SNPs in exon 26 (C3435T) and exon 21 (G2677T/A), suggesting that the observed differences in P-gp, initially attributed to the exon 26 SNP, may be the result of the associated polymorphism in exon 21. Furthermore, several groups have subsequently confirmed the existence of such distinct haplotypes, with three common haplotypes found in more than 70% of individuals. It has also been recently shown that a synonymous SNP in exon 12 (C1236T) is linked to the C3435T and G2677T/A SNPs. Available data indicate that the allele frequencies of these three main variants differ considerably in the various populations. Of note, marked differences of the C3435T SNP allele frequency have been observed with an increased frequency of the C allele (wild type) in African populations compared with Caucasian-Asian populations. Similarly, the 2677A genotype of the G2677T/A SNP is significantly more common in Japanese subjects, while the variant 1236T is much more frequent in Asian subjects compared to Caucasian subjects. The study of Hoffmeyer et al. was the first to demonstrate a 2-fold reduction in P-gp expression in duodenal biopsy samples among healthy Caucasian subjects homozygous for the exon 26.3435T allele. Those subjects were also shown to have increased digoxin plasma concentrations after oral administration, suggesting greater drug absorption in individuals with low intestinal P-gp levels. However, the replication of this finding has been controversial with consistent and conflicting studies. In a study quantifying MDR1 mRNA in the duodenum, Nakamura et al. showed, in contrast to the Hoffmeyer’s findings, greater levels in healthy Japanese subjects carrying the 3435T allele as compared with subjects with the C3435T allele of the exon 26. This controversy, however, is not limited to the Asian population, as conflicting data have been noted also for others P-gp substrates including fexofenadine, cyclosporine and tacrolimus. Similarly conflicting data have also been reported for the exon 21 polymorphisms concerning the digoxin, tacrolimus, cyclosporine, and multiple drugs pharmacokinetics. Furthermore, conflicting data have also been obtained when evaluating the P-gp or mRNA mucosal expression with studies demonstrating increased or unchanged P-gp function for mutant C3435T SNP. Functional studies investigating the contribution of G2677T/A polymorphism also accounted for conflicting results. Possible reasons for such discrepancies are the existence of gene-gene interaction, linkage disequilibrium between C3435T SNP and other MDR1 SNPs, and environmental factors influencing also the CYP enzyme activity. Moreover, it should be noted that regulation of P-gp expression might significantly differ from tissue to tissue. For example, the ligand-activated nuclear receptor PXR is thought to be critical to P-gp expression in the liver and intestine, whereas in sites such as blood-brain barrier, PXR is unlikely to display regulatory functions. Finally, the methodology used to measure P-gp expression widely differs between studies. In addition different substrate drugs have been used in various studies, with different route of administration and potential different extent of metabolism relative to P-gp-mediated transport. For example, cyclosporine not only is transported by P-gp but also it is a substrate of CYP3A4, thus a potential P-GP effect may be masked by CYP3A4 activity.

**MDR1 AND INFLAMMATORY BOWEL DISEASE**

The MDR1 gene is an attractive candidate gene for the pathogenesis of IBD and perhaps response to therapy, with evidences at both functional and genetic levels. In a German case-control study Schwab et al investigating the C3435T polymorphism firstly reported an increase of the T allele and TT genotype frequencies in 149 patients with ulcerative colitis, but not Crohn’s disease, compared with controls (P = 0.049, OR = 1.4; P = 0.005, OR = 2.1, respectively). Subsequent studies, however, have gained conflicting results: Glas et al. in a small group of 123 patients with UC found results in partial accordance with a trend towards an increased frequency of T allele compared to healthy controls, but a statistical difference was obtained only in one of two different control groups (T allele, P = 0.018; TT genotype, P = 0.016), thus suggesting the key factor of patients and controls recruitment. In a small
Greek study\(^{[90]}\) no difference was found in both UC and CD patients, but this study has been criticized because the investigated populations were not in Hardy-Weinberg equilibrium. A large study\(^{[99]}\) performed in a German and British cohort investigating 307 UC and 564 CD patients by using both a case-control strategy and a transmission disequilibrium test based analysis (which is more resilient to latent effects such as population stratification), failed to demonstrate an association, even after stratifying individuals on the basis of CARD15 gene variants. More recently Ho et al\(^{[71]}\) confirmed the association in UC patients (\(P = 0.04, OR = 1.6\) for TT genotype), especially those with extensive colitis (\(P = 0.003, OR = 2.64\)), but in contrast completely negative findings have been reported in large studies from North America\(^{[72]}\), Slovenia\(^{[93]}\) and Italy\(^{[72]}\). In particular in the latter study from our Institution, about one thousand IBD patients have been genotyped (Tables 2 and 3) with negative results. In addition, Urcelay et al\(^{[70]}\) paradoxically found a significant association of the CC3435 genotype (wild) in CD patients (\(P = 0.007\)), but data were not in Hardy-Weinberg equilibrium.

In a multicenter North American cohort with 444 IBD trios, Brant et al\(^{[72]}\) investigated also another polymorphism of MDR1, the tri-allelic G2677/T/A SNP (Ala893Ser/Thr). They found a significant association of the Ala893 variant (G2677), known to decrease transporter function, with IBD in both case-control analysis (\(P = 0.002\)) and the pedigree disequilibrium test (PDT) (\(P = 0.0002\)), especially in non-Jewish subjects. The association was confirmed by PDT analysis within the CD subset (\(P = 0.001\)) with a similar, non-significant trend in the small subset of UC patients. Curiously, an association with another allele (T allele, 893Ser variant) of this SNP was found in UC patients (\(P = 0.029\)) by Potočnik et al\(^{[73]}\). Ho et al\(^{[71]}\), did not find an association between this polymorphism and IBD; however, a 2-locus haplotype (3435T/G2677) was significantly associated with UC in this study (\(P = 0.03\)). Urcelay et al\(^{[70]}\) similarly did not found a correlation between this polymorphism and IBD; however, a trend towards an increased frequency of 2677T/3435T haplotype was found in CD patients. In contrast, more recently Palmieri et al\(^{[79]}\) did not find any association of this polymorphism and 2-locus haplotype with IBD patients (Table 3). Reasons for this discrepancy may lie in population heterogeneity, sample size, selection of control population, incomplete phenotype description, and difficulty to replicate results in case control study when the contribution of the genetic predisposing factor under investigation is weak. Accordingly, when looking for example at the existing data on C3435T polymorphism, it is apparent that the 5%-8% difference of the “risk” allele and genotype frequencies in UC patients and their significance (\(P\) values ranging from 0.02 to 0.049) are rather modest. More importantly, there is a significant heterogeneity in patients (T allele frequency ranging from 42.3% up to 65.3% in UC) and especially control populations (T allele frequency ranging from 35.7% up to 63%).

The hypothesis that altered PGP expression in IBD patients could modify the response to medical therapy was put forward by Farrell et al\(^{[73]}\). Peripheral blood lymphocytes (PBL) from patients with active Crohn’s disease (CD) and Ulcerative colitis (UC) in whom medical therapy had failed and surgical intervention had been necessary were shown to have higher expression of P-gp glycoprotein compared with those from patients who had inactive disease and required surgery for obstruction or dysplasia. Based on this observation the authors speculated that poor response to glucocorticoids in IBD might relate in part to constitutive MDR1 expression. We have recently challenged this hypothesis in a large cohort of IBD patients\(^{[74]}\) using steroids, by evaluating both C3435T and G2677T/A polymorphisms. Allele and genotype frequencies were compared in 594 patients using systemic steroids, subgrouped in 320 responders, 76 non-responders and 198 steroid-dependent. No significant differences were found within subgroups and between subgroups and 450 healthy subjects. Moreover, 297 patients taking immunosuppressive drugs (included azathioprine, 6-mercaptopurine, methotrexate, and cyclosporine) were also evaluated. No influence of MDR1 genotypes was found with respect to response to therapy. Similarly, in a recent study by Mc

### Table 2: Distribution of C3435T alleles and genotypes (cases and controls) in the existing literature

| Glas, 2003 | C | T | CC | CT | TT |
|-----------|---|---|----|----|----|
| UC = 123\(^{[71]}\) | 111 (45) | 135 (55) | 19 (7) | 73 (30) | 61 (25) |
| CD = 135 | 130 (48) | 140 (52) | 26 (19) | 78 (58) | 31 (23) |
| IBD = 258 | 241 (47) | 275 (53) | 15 (7) | 151 (59) | 62 (24) |
| HC = 265 | 272 (51) | 258 (49) | 70 (26) | 132 (50) | 63 (24) |

| Schwab, 2003 | C | T | CC | CT | TT |
|-------------|---|---|----|----|----|
| UC = 149 | 129 (43) | 169 (57) | 26 (17) | 77 (52) | 46 (31) |
| CD = 149 | 154 (52) | 144 (48) | 39 (26) | 76 (51) | 34 (23) |
| IBD = 126 | 134 (53) | 118 (47) | 33 (26) | 66 (54) | 25 (20) |
| HC = 126 | 128 (51) | 124 (49) | 35 (28) | 58 (46) | 33 (26) |
| IBD = 275 | 263 (48) | 287 (52) | 59 (21) | 145 (53) | 71 (26) |
| HC = 275 | 282 (51) | 268 (49) | 74 (27) | 134 (49) | 67 (24) |

| Ho, 2005 | C | T | CC | CT | TT |
|----------|---|---|----|----|----|
| UC = 335 | 280 (42) | 390 (58) | 61 (18) | 158 (47) | 116 (35) |
| CD = 268 | 252 (47) | 284 (53) | 56 (21) | 140 (52) | 72 (27) |
| IBD = 603 | 532 (44) | 674 (56) | 117 (19) | 298 (50) | 188 (31) |
| HC = 370 | 354 (48) | 386 (52) | 82 (22) | 190 (51) | 98 (27) |

| Palmieri, 2005 | C | T | CC | CT | TT |
|---------------|---|---|----|----|----|
| UC = 468 | 488 (52) | 448 (48) | 124 (27) | 240 (51) | 104 (22) |
| CD = 478 | 503 (53) | 453 (47) | 125 (26) | 253 (53) | 100 (21) |
| IBD = 946 | 991 (52) | 901 (48) | 249 (26) | 493 (52) | 204 (22) |
| HC = 450 | 470 (52) | 430 (48) | 115 (26) | 240 (53) | 95 (21) |

| Potočnik, 2004 | C | T | CC | CT | TT |
|----------------|---|---|----|----|----|
| UC = 144 | 134 (47) | 154 (53) | - | - | - |
| CD = 163 | 161 (49) | 165 (51) | - | - | - |
| IBD = 307 | 295 (48) | 319 (52) | - | - | - |
| HC = 355 | 376 (53) | 334 (47) | - | - | - |

| Urcelay, 2006 | C | T | CC | CT | TT |
|---------------|---|---|----|----|----|
| UC = 311 | 317 (51) | 305 (49) | 87 (28) | 143 (46) | 81 (26) |
| CD = 303\(^{[72]}\) | 369 (61) | 237 (39) | 122 (40) | 122 (40) | 56 (19) |
| IBD = 614 | 686 (56) | 542 (44) | 209 (34) | 286 (44) | 137 (22) |
| HC = 324 | 344 (53) | 304 (47) | 97 (30) | 150 (46) | 77 (24) |

UC = Ulcerative colitis, CD = Crohn’s disease, HC = healthy controls. \(P = 0.045\) (T vs CC), \(P = 0.049\) (TT vs CC). \(P = 0.02\) (T vs C), \(P = 0.04\) (TT vs CC). \(P = 0.006\) (T vs C), \(P = 0.01\) (TT vs CC). \(^{[70]}\) Subjects not in Hardy-Weinberg equilibrium.
Table 3  Distribution of G2677T/A alleles and genotypes (cases and controls) in the existing literature

| A | G | T | AA | GG | GT | TT | GA | TA |
|---|---|---|----|----|----|----|----|----|
| Brant, 2003 | | | | | | | | |
| IBD_NJ = 211 | 2 (0.5) | 254 (60.2) | 166 (39.3) | - | 76 (36) | 101 (48) | 32 (15) | 1 (0.5) |
| HC_NJ = 392 | 20 (2.6) | 411 (52.4) | 355 (45) | - | 108 (27) | 183 (47) | 81 (21) | 12 (3) |
| IBD_J = 114 | 1 (0.5) | 143 (62.7) | 84 (36.8) | - | 11 (36) | 60 (53) | 12 (10) | 1 (1) |
| HC_J = 219 | 13 (0.7) | - | 265 (60.5) | 160 (35.6) | - | 85 (39) | 89 (41) | 32 (15) |
| Ho, 2005 | | | | | | | | |
| UC = 335 | - | 366 (54.6) | 304 (45.4) | - | 95 (28.3) | 176 (52.5) | 64 (19.1) | - |
| CD = 268 | - | 283 (52.8) | 253 (47.2) | - | 75 (27.9) | 133 (47.8) | 60 (22.4) | - |
| IBD = 603 | - | 649 (53.8) | 557 (46.2) | - | 170 (28.2) | 309 (51.2) | 124 (20.6) | - |
| HC = 370 | - | 378 (51.2) | 362 (48.9) | - | 102 (27.6) | 174 (47.0) | 94 (25.4) | - |
| Palmieri, 2005 | | | | | | | | |
| A | G | T | AA | GG | GT | TT | GA | TA |
| Poteckin, 2004 | | | | | | | | |
| UC = 144 | - | 157 (54) | 131 (46) | - | - | - | - | - |
| CD = 163 | - | 187 (57) | 139 (43) | - | - | - | - | - |
| IBD = 307 | - | 344 (56) | 270 (44) | - | - | - | - | - |
| HC = 355 | - | 424 (59.7) | 286 (40.3) | - | - | - | - | - |
| Urcelay, 2006 | | | | | | | | |
| UC = 311 | 4 (0.7) | 372 (62.8) | 216 (36.5) | 0 (0) | 118 (39.9) | 133 (44.9) | 41 (13.9) | 3 (1) |
| CD = 303 | 6 (0.9) | 403 (63.2) | 229 (35.9) | 0 (0) | 139 (43.6) | 122 (38.3) | 52 (16.3) | 3 (0.9) |
| IBD = 615 | 10 (0.8) | 775 (63) | 445 (36.2) | 0 (0) | 257 (41.8) | 255 (41.5) | 93 (16.1) | 6 (0.9) |
| HC = 352 | 8 (1.1) | 426 (60.5) | 270 (38.4) | 0 (0) | 140 (39.8) | 142 (40.3) | 62 (17.6) | 4 (1.1) |

*P = 0.03 (G vs T); P = 0.08 (GG vs GT TT).

Table 4  Summary of ORs and 95% CIs for different outcomes obtained at the meta-analysis

| Outcome CD | Fixed effects | Random effects | Heterogeneity test |
|---|---|---|---|
| | P value | OR (95% CI) | P value | OR (95% CI) | 0.09 |
| C343ST | T vs C (6 studies) | 0.519 | 0.968 (0.878-1.068) | 0.722 | 0.974 (0.842-1.126) |
| G2677T/A | TT vs CC (5 studies) | 0.297 | 0.892 (0.720-1.106) | 0.472 | 0.900 (0.675-1.200) NS |
| | G vs T (4 studies) | 0.635 | 1.027 (0.920-1.145) | 0.635 | 1.027 (0.920-1.145) |
| | GG vs GT TT (3 studies) | 0.338 | 1.092 (0.912-1.308) | 0.338 | 1.092 (0.912-1.308) |
| Outcome UC | T vs C (6 studies) | 0.002 | 1.170 (1.062-1.289) | 0.003 | 1.178 (1.058-1.311) NS |
| | TT vs CC (5 studies) | 0.008 | 1.132 (1.080-1.164) | 0.176 | 1.367 (1.057-1.768) |
| G2677T/A | G vs T (4 studies) | 0.843 | 0.898 (0.887-1.103) | 0.862 | 0.986 (0.836-1.162) NS |
| | GG vs GT TT (3 studies) | 0.947 | 0.994 (0.830-1.190) | 0.947 | 0.994 (0.830-1.190) |
| Outcome IBD | T vs C (6 studies) | 0.083 | 1.074 (0.991-1.165) | 0.135 | 1.083 (0.976-1.201) NS |
| | TT vs CC (5 studies) | 0.225 | 1.116 (0.935-1.332) | 0.274 | 1.135 (0.904-1.426) NS |
| | G vs T (5 studies) | 0.351 | 1.041 (0.957-1.132) | 0.448 | 1.047 (0.950-1.178) NS |
| | GG vs GT TT (4 studies) | 0.366 | 1.065 (0.929-1.221) | 0.366 | 1.065 (0.929-1.221) NS |

Govern et al in which the need for colectomy in UC patients was used as a surrogate marker for glucocorticoids resistance, no association was found with C343ST polymorphism.[77]

Although the Farrell’s hypothesis is attractive, data from our study strongly question the influence of MDR1 gene on response to steroid therapy in IBD patients. There are, indeed, also some caveats to the Farrell’s study; firstly, circulating lymphocytes consist of different subsets of lymphocytes which express MDR1 at varying levels, since it is now established that lymphocytes homing to the gut associated lymphoid tissue are phenotypically distinct from circulatory ones. Accordingly, Yacyshyn et al[78] have demonstrated different level of MDR1 expression and activity in intraepithelial, lamina propria, and PBL. Overall, intraepithelial MDR1 expression and function were lower in UC compared with CD and healthy controls. Accordingly, Langman et al found a down-regulation of MDR1 tissue expression in UC patients[39]. Moreover, the effect of corticosteroids or other treatment used in IBD on MDR1 expression it is not fully established. It remains therefore to be evaluated whether different expression of P-gp reflects
a secondary phenomenon to therapy or a primary one, influencing the response to treatment. Finally, increased expression does not necessarily imply increased function in diseased states. Based on the available evidence, the contribution of MDR1 gene on IBD predisposition and response to medical therapy, although biologically plausible is still unproven.

META-ANALYSIS

In the attempt to evaluate the potential association of C3435T and G2677T/A polymorphisms with IBD, a meta-analysis has been performed. Because case-control studies were included, the odds ratios (ORs) were employed. For each outcome, the between-study heterogeneity across all the eligible comparisons has been performed by using the chi-square based Q statistic; heterogeneity was considered significant for \( p < 0.10 \). Data were combined by using both fixed and random effects models; random effects are more appropriate when heterogeneity is present. Analysis was conducted by Comprehensive Meta Analysis v.1.0.23, 1999 Biostat software (www.meta-analysis.com).

In Tables 2 and 3 are depicted the characteristics of the studies included in the meta-analysis, with the allele and genotype frequencies. The study by Gazouli et al.\(^6\) has been excluded due to failure of Hardy-Weinberg equilibrium. The study of Croucher et al.\(^8\) was also excluded due to lack of data concerning allele and genotype frequencies, also upon specific request to the authors. For the study of Brant et al.\(^6\) data are expressed as whole IBD, since no complete information for UC and CD subgroups were available.

When comparing allele (T vs C) and genotype frequencies (TT vs CC) of the C3435T SNP in CD and UC patients, a slight but significant difference was found in the pooled data (Table 4). More specifically a significant association with T allele (OR 1.17, CI 1.06-1.31, \( p = 0.003 \)) and TT genotype (OR = 1.36, CI 1.05-1.76, \( p = 0.017 \)) was demonstrated. In contrast no association in CD patients was found and in IBD patients as whole. Similarly no significant difference was found after pooling data of the available studies for allele and genotype frequencies of the G2677T/A SNP (Figures 1 and 2).

ACKNOWLEDGMENTS

Ms Ermelinda De Santo, Ms Tiziana Latiano, Ms Carla Zagaria and Mr Giuseppe Corritore for their skilled technical support; Dr. Lazzaro di Mauro of the Medicina Trasfusionale OO RR Foggia for providing blood donors DNA samples.

REFERENCES

1. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997; 8: 161-170
2. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci 1992; 17: 18-21
3. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-162
4. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987; 84: 3004-3008
5. Thiebau E, Tsuuro T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735-7738
6. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989; 86: 695-698
7. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuuro T, Itoyama S, Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK. Cancer Res 1988; 48: 1926-1929
8. Klimecki WT, Futschek BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-2458
9. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13-33
10. Chianale J, Vollrath V, Wieland AM, Miranda S, Gonzalez R, Fresno AM, Quintana C, Gonzalez S, Andrade L, Guzman S. Differences between nuclear run-off and mRNA levels for multidrug resistance gene expression in the cephalocaudal
axis of the mouse intestine. Biochim Biophys Acta 1995; 1264: 369-376
11 Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 1996; 118: 1841-1847
12 Fojo AT, Ueda K, Slamov DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987; 84: 265-269
13 Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, Terwilliger JD, Lathrop GM, Bell JL, Jewell DP. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996; 14: 199-202
14 Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733-5744
15 Shomer NH, Dangler CA, Mariné RP, Fox JG. Helicobacter bilis/Helicobacter rodentium co-infection associated with diarrhea in a colony of scid mice. Lab Anim Sci 1998; 48: 455-459
16 Kim R, Wilkinson G. Pharmacogenetics of drug transporters. In: Kalow W, Meyer UA, Tyndale RF, editors. Pharmacogenomics. New York: Marcel Dekker, 2001: 81-108
17 Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997; 153: 357-365
18 Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524
19 Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997; 94: 2031-2035
20 Verschraagen M, Kosks CH, Schellens JH, Beijnen JH. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999; 40: 301-306
21 Ueda K, Okamura M, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Horii R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267: 2424-2425
22 Bourgeois S, Grulo DJ, Newby RF, Rajah FM. Expression of an mdr gene is associated with a new form of resistance to digoxin-verapamil. Mol Endocrinol 1993; 7: 840-851
23 Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735-2739
24 Norris MD, De Graaf D, Haber M, Kavallaris M, Madaffiglio J, Gilbert J, Kwan E, Wu J, Mechetner EB, Gudkov AV, Roninson IB. Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer 1996; 65: 613-619
25 Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 1987; 77: 142-144
26 Chin JE, Soiffer R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDRI (P-glycoprotein) gene family. Mol Cell Biol 1989; 9: 3808-3820
27 Kioka N, Tsubota J, Kakemi Y, Komano T, Gottesman MM, Pastan I, Ueda K. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Comm 1989; 162: 224-231
28 Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001; 2: 51-64
29 Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD, Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Update 2003; 6: 71-84
30 Ishikawa T, Onishi Y, Hirano H, Ososumi K, Nagakura M, Tarui S. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol Pharm Bull 2004; 27: 939-948
31 Hoffmeyer S, Burk O, van Richter O, Arnold HP, Brockmöller J, Johne A, Casconi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 5473-5478
32 Kim RB, Leake BF, Choo EF, Dresser GK, Kubbba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199
33 Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137-1143
34 Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroezer HK, Casconi I. The effects of the human MDRI genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572-583
35 Gaikovitch EA, Casconi I, Mrozikiewicz PM, Brockmüller J, Frötschi R, Köpke K, Gerloff T, Chernov JN, Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003; 59: 303-312
36 Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K. C3435T polymorphism in the MDRI gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451-457
37 Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schäkel U, Ehninger G, Schäich M. MDRI gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955-4962
38 Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M. Frequency of C3435T polymorphism of MDRI gene in African people. Lancet 2001; 358: 383-384
39 Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folyan GO, Githång’a J, Indalo A, Ofotir-Adjei D, Price-Evans DA, McLeod HL. MDRI pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221
40 Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K. Effects of polymorphisms of MDRI, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 2002; 25: 1356-1359
41 Tang K, Ngoi SM, Gwye PC, Chua JM, Lee EJ, Chong SS, Lee CG. Distinct haplotype profiles and strong linkage disequilibrium at the MDRI multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenomics 2002; 12: 437-450
42 Johne A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockmüller J, Casconi I, Roots I. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDRI gene. Clin Pharmacol Ther 2002; 72: 584-594
43 Verstuyft C, Schwab M, Brinkmann U, Jallion P, Funck-Brentano C, Becquement L. Digoxin pharmacokinetics and MDRI genetic polymorphisms. Eur J Clin Pharmacol 2003; 58: 809-812
polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther 2005; 22: 1129-1138
75 Urcelay E, Mendoza JL, Martín MC, Mas A, Martínez A, Taxonera C, Fernandez-Arquero M, Díaz-Rubio M, de la Concha EG. MDR1 gene: susceptibility in Spanish Crohn’s disease and ulcerative colitis patients. Inflamm Bowel Dis 2006; 12: 33-37
76 Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O’Ttoole D, Mahmud N, Keeling PW, Weir DG, Kelleher D. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000; 118: 279-288
77 McGovern DP, Ahmad T, Van Heel D, Negoro K, Jewell D. Cytochrome p450 and multidrug-resistance gene 1 (MDR-1) polymorphisms: predictors of the need for colectomy in ulcerative colitis? Gastroenterology 2002; 122: W1313
78 Yacyshyn B, Maksymowych W, Bowen-Yacyshyn MB. Differences in P-glycoprotein-170 expression and activity between Crohn’s disease and ulcerative colitis. Hum Immunol 1999; 60: 677-687
79 Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, Schmitz G. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004; 127: 26-40

S- Editor Pan BR  E- Editor Ma WH